| Drug Type siRNA | 
| Synonyms SCAP siRNA, LY 3885125, LY3885125 | 
| Target | 
| Action modulators | 
| Mechanism SCAP modulators(SREBF chaperone modulators) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Dyslipidemias | Phase 1 | United States  | 10 Aug 2023 | |
| Metabolic dysfunction-associated steatotic liver disease | Phase 1 | United States  | 10 Aug 2023 | 





